• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

作者信息

Duchmann M, Braun T, Micol J-B, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas P-Y, Guieze R, Chretien M-L, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R

机构信息

Université Paris Diderot, Paris, France.

Service d'hématologie, Hôpital Avicenne, Université Paris XIII, Assistance Publique Hôpitaux de Paris, Bobigny, France.

出版信息

Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41.

DOI:10.1038/bcj.2017.41
PMID:
28498370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5518885/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69c3/5518885/df75437d9e82/bcj201741f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69c3/5518885/df75437d9e82/bcj201741f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69c3/5518885/df75437d9e82/bcj201741f1.jpg

相似文献

1
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.根据国际MDS/MPN联盟标准对接受去甲基化药物治疗的慢性粒单核细胞白血病患者反应评估的验证
Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41.
2
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.低剂量地西他滨与低剂量阿扎胞苷治疗低危骨髓增生异常综合征和骨髓增生异常综合征/骨髓增殖性肿瘤的随机2期研究
Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3.
3
The euphoria of hypomethylating agents in MDS and AML: is it justified?低甲基化药物在 MDS 和 AML 中的兴奋：这合理吗？
Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15.
4
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.低剂量地西他滨三种给药方案用于高危骨髓增生异常综合征和慢性粒单核细胞白血病的随机研究结果
Blood. 2007 Jan 1;109(1):52-7. doi: 10.1182/blood-2006-05-021162. Epub 2006 Aug 1.
5
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.阿扎胞苷对比利时高危骨髓增生异常综合征、急性髓系白血病或慢性粒单核细胞白血病患者的安全性和有效性：一项真实、非干预性上市后调查的结果
Acta Clin Belg. 2015 Feb;70(1):34-43. doi: 10.1179/2295333714Y.0000000102. Epub 2014 Dec 2.
6
Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.基于全基因组单核苷酸多态性微阵列的核型分析在骨髓增生异常综合征和慢性粒单核细胞白血病中的应用及其对去甲基化治疗后治疗结局的影响。
Ann Hematol. 2013 Apr;92(4):459-69. doi: 10.1007/s00277-012-1635-7. Epub 2012 Dec 23.
7
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.阿扎胞苷治疗骨髓增生异常综合征、慢性粒单核细胞白血病和急性髓系白血病。
Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10.
8
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.阿扎胞苷治疗失败后接受地西他滨治疗的高危骨髓增生异常综合征（MDS）和晚期慢性粒单核细胞白血病（CMML）患者的结局
Leuk Res. 2015 May;39(5):501-4. doi: 10.1016/j.leukres.2015.02.004. Epub 2015 Feb 16.
9
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.根据重叠型骨髓增生异常/骨髓增殖性肿瘤标准，慢性粒单核细胞白血病患者对阿扎胞苷的反应。
Leuk Res. 2022 May;116:106836. doi: 10.1016/j.leukres.2022.106836. Epub 2022 Mar 26.
10
Activity of azacitidine in chronic myelomonocytic leukemia.阿扎胞苷在慢性粒单核细胞白血病中的活性。
Cancer. 2011 Jun 15;117(12):2690-6. doi: 10.1002/cncr.25759. Epub 2010 Dec 23.

引用本文的文献

1
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management.骨髓增生异常综合征/骨髓增殖性肿瘤重叠综合征：诊断与管理实用指南
Leukemia. 2025 Apr 19. doi: 10.1038/s41375-025-02620-8.
2
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.骨髓增生异常/骨髓增殖性肿瘤的基因组景观可预测低甲基化剂治疗的反应。
Leuk Lymphoma. 2022 Aug;63(8):1942-1948. doi: 10.1080/10428194.2022.2057488. Epub 2022 Apr 4.
3
Treatment advances for pediatric and adult onset neoplasms with monocytosis.

本文引用的文献

1
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.一份关于成人骨髓增生异常/骨髓增殖性肿瘤（MDS/MPN）统一反应标准的国际联盟提案。
Blood. 2015 Mar 19;125(12):1857-65. doi: 10.1182/blood-2014-10-607341. Epub 2015 Jan 26.
2
Prognostic score including gene mutations in chronic myelomonocytic leukemia.包含基因突变的慢性髓单核细胞白血病预后评分。
J Clin Oncol. 2013 Jul 1;31(19):2428-36. doi: 10.1200/JCO.2012.47.3314. Epub 2013 May 20.
3
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.
伴有单核细胞增多的小儿和成人发病肿瘤的治疗进展。
Curr Hematol Malig Rep. 2021 Jun;16(3):256-266. doi: 10.1007/s11899-021-00622-8. Epub 2021 Mar 16.
4
Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.慢性髓单核细胞白血病：生物学、预后因素和治疗的新见解。
Curr Oncol Rep. 2019 Nov 14;21(11):101. doi: 10.1007/s11912-019-0855-6.
5
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.成人慢性粒单核细胞白血病的诊断与治疗：欧洲血液学协会和欧洲白血病网的建议
Hemasphere. 2018 Nov 29;2(6):e150. doi: 10.1097/HS9.0000000000000150. eCollection 2018 Dec.
6
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.高危慢性粒单核细胞白血病患者在转化为急性髓系白血病之前接受地西他滨治疗的结果：一例报告
Oncol Lett. 2018 May;15(5):7132-7138. doi: 10.3892/ol.2018.8236. Epub 2018 Mar 12.
7
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.基因突变在接受低甲基化剂治疗的慢性粒单核细胞白血病患者中的预后作用。
EBioMedicine. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25.
在 AZA-001 随机试验中，接受阿扎胞苷或常规治疗方案治疗的高危骨髓增生异常综合征患者的反应与生存之间的关系的多变量分析。
Haematologica. 2013 Jul;98(7):1067-72. doi: 10.3324/haematol.2012.074831. Epub 2013 Apr 12.
4
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.阿扎胞苷治疗慢性粒单核细胞白血病患者的反应和生存的预测因素。
Leuk Res. 2013 Jun;37(6):609-13. doi: 10.1016/j.leukres.2013.01.004. Epub 2013 Feb 12.
5
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.骨髓增殖性肿瘤 (MPN) 症状评估表总症状评分：在 MPN 患者中前瞻性国际评估简化症状负担评分系统。
J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15.
6
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.107 例接受 JAK1/JAK2 抑制剂芦可替尼治疗的骨髓纤维化患者的长期结果：与匹配的历史对照相比具有生存优势。
Blood. 2012 Aug 9;120(6):1202-9. doi: 10.1182/blood-2012-02-414631. Epub 2012 Jun 20.
7
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.地西他滨治疗晚期慢性粒单核细胞白血病反应的分子预测因子：一项 2 期试验。
Blood. 2011 Oct 6;118(14):3824-31. doi: 10.1182/blood-2011-05-352039. Epub 2011 Aug 9.
8
Activity of azacitidine in chronic myelomonocytic leukemia.阿扎胞苷在慢性粒单核细胞白血病中的活性。
Cancer. 2011 Jun 15;117(12):2690-6. doi: 10.1002/cncr.25759. Epub 2010 Dec 23.
9
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.在 282 例接受阿扎胞苷治疗的高危骨髓增生异常综合征患者中，预测反应和总生存的预后因素。
Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.
10
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.阿扎胞苷与传统治疗方案治疗高危骨髓增生异常综合征的疗效比较：一项随机、开放标签的III期研究。
Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21.